System for neurological investigations

Likvor

Likvor is a medical device company that has developed a system for neurological investigations. The CELDA System is the result of close to 40 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. Normal Pressure Hydrocephalus, NPH, is easily misdiagnosed as dementia, Parkinson's or Alzheimer's disease. NPH can be treated by inserting a shunt and is therefore called "treatable dementia". The Likvor CELDA™ System is a valuable tool in the diagnosis of NPH.

Likvor

CEO:

Maria Wallin Wållberg

First investment year:

2011

Business sector:

Life Science, Medtech

Investment manager: Mattias Eriksson Visit website